FCX vs XBIO · P/E 38, rev $13.26B vs rev $1.5M
Freeport-McMoran Copper & Gold Inc (FCX) versus Xenetic Biosciences Inc (XBIO) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Xenetic Biosciences Inc (XBIO) is a biotechnology company listed on US.
Latest reported FCX revenue for 2026-06-30 was $13.26B. Net income was $1.86B. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported XBIO revenue for 2026-06-30 was $1.5M. Net income was -$1.4M. Revenue was up 81.9% from 2026-03-31 to 2026-06-30. XBIO currently screens at market cap $5.7M.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. XBIO currently screens at market cap $5.7M.
Not investment advice. Open the FCX and XBIO stock pages for the full models.
Not investment advice.